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bHonorary Editor, Indian Heart JournalPlatelets play central role in thrombotic events in acute coro-
nary syndromes (ACS) and during percutaneous coronary in-
terventions (PCI). Platelet activation occurs through various
mechanisms and all culminate in expression of the surface GP
IIb-IIIa receptors which mediate their aggregation and throm-
bosis. Glycoprotein IIb-IIIa inhibitors (GPI) remain the most
powerful antiplatelet agents by inhibiting this final common
pathway of platelet activation. The role of GPI in the treatment
of coronary ischemic events has evolved through the past 20
years. Given their potent antiplatelet activity and consistent
anti-ischemic benefit inmajor trials, theywere an integral part
of antiplateleteantithrombinportfolio in the treatmentofACS
and during PCI over a decade. However, the advent of stents
and thienopyridine ticlopidine and later clopidogrel made
periprocedural ischemic complications less common and GPI
had slowly lost its importance in routine low-risk PCI. Though
GPI reduced periprocedural ischemic complications, increased
bleeding events continued to be amajor problem. In the recent
years, bleeding has increasingly been recognized as a major
determinant of clinical outcomes both with ACS and PCI.
Recently, the availability of bivalirudin as an equally effective
and safer periprocedural anticoagulant, heparin and GPI have
slowlybeenpushed to secondplaceover theentire spectrumof
coronary interventions. Thenewerantiplateletswhichprovide
rapid and more consistent antiplatelet action further reduced
the role ofGPI to a very small subset of patientswhere ischemic
risk far exceeds the thrombotic risk.1e3 This editorial briefly
evaluates the current role of GPI in the background of recent
major studies with newer antiplatelets and bivalirudin.1. Elective PCI
GPI ruled the era of plain balloon angioplasty where acute
closure was the main threat to the interventionist. The* Corresponding author.
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were introduced into the interventional practice. Though this
brought downGPI usage substantially, they continued to be an
important part of periprocedural antithrombin-antiplatelet
treatment. Two major trials in the last decade questioned
the practice of routine periprocedural use of GPI in non-acute
PCI where effective platelet inhibition can be achieved with
optimal clopidogrel loading. The ISAR-REACT trial tested the
role of abciximab in 2159 patients undergoing elective low-
risk PCI after preloading with 600 mg of clopidogrel. Abcix-
imab failed to show any reduction in the primary end point of
30-day incidence of major adverse cardiac events compared
with placebo. Further, it increased the incidence of thrombo-
cytopenia and blood transfusions.4 The ISAR-SWEET trial
examined the same strategy in 701 diabetic patients. Again
abciximab did not improve outcomes in the setting of clopi-
dogrel loading at least 2 h prior to the procedure.5 In contrast,
a recent meta-analysis of 22 studies involving 10,123 patients
showed significant reduction in non-fatal myocardial infarc-
tion at the expense of significant increase in minor bleeding
events with GPI over and above dual antiplatelets.6 With the
available evidence, the current guidelines do not recommend
routine use of GPI in elective low and intermediate risk PCI if
the patients are optimally preloaded with clopidogrel.72. Unstable angina and non-ST-segment
elevation myocardial infarction
GPI had consistently been shown to be beneficial in patients
with unstable angina (UA) and non-ST-segment elevation
myocardial infarction (NSTEMI). This led to wide spread use of
these agents both in medically treated patients and upstream
to the planned procedure. However, a meta-analysis of 29,570
patients by Roffi et al,8 in 2002 showed that the utility of GPIty of India. All rights reserved.
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practice was re-evaluated in two recent trials, ACUITY e
timing9 and EARLY ACS10; they did show any advantage with
routine upstream therapy with GPI compared to selective
administration in the catheterization laboratory in the back-
ground of optimal dual antiplatelet preloading. In addition,
upstream therapy was associated with increased bleeding
events. Further, ISAR-REACT-2 trial investigated the utility of
abciximab given in catheterization laboratory in patients
optimally loaded with dual antiplatelets. There was a 25%
statistically significant relative reduction in the primary
endpoint of death, myocardial infarction or urgent revascu-
larization and this benefit was confined to only patients with
elevated troponin levels.11 The current guidelines recom-
mends GPI only in patients with high risk features such as
elevated troponin and angiographically visible thrombus and
those not pre-treatedwith thienopyridines. Upstream therapy
may be considered only in patients with on-going ischemia
and the risk of bleeding is low.12,133. ST-segment elevation myocardial
infarction
The trials of ‘pre dual antiplatelet’ era showed clinical benefit
of routine GPI, both upstream and periprocedural, in the
setting of primary PCI. However, recent data does not support
this practice. The upstream administration of GPI was evalu-
ated in two trials. In the On-TIME 2 trial, the patients were pre-
treated with a loading dose of clopidogrel and randomized to
prehospital administration of tirofiban infusion vs placebo.
Tirofiban infusion improved ST-segment resolution at 1 h
after PCI. Though it fails to demonstrate improvement in
survival or rate of reinfarction, there was reduction in the
incidence of early stent thrombosis and urgent PCI.14 In the
BRAVE-3 trial, upstream administration of abciximab was
evaluated against placebo in patients pre-treated with 600 mg
of clopidogrel loading and heparin. There was no difference in
the primary endpoint of reduction in infarct size or in the
secondary end point of 30-day incidence of death, myocardial
infarction or urgent revascularization.15 In addition, therewas
increased incidence of thrombocytopenia and minor bleeding
in the abciximab arm. With this background, the current
guidelines recommended GPI for selected patients with high
risk angiographic features and those not optimally loaded
with dual antiplatelets.16,174. Bivalirudin vs heparin D GPI
Bivalirudin is a synthetic, direct thrombin inhibitor that
binds specifically and reversibly to both clot-bound and free
thrombin. It has been evaluated as an alternative to
heparin þ GPI in patients undergoing both urgent and elective
PCI. In the REPLACE-2 trial, bivalirudin with provisional use of
GPI (abciximab) was tested against low-dose unfractionated
heparin (UFH) plus planned GPI in both stable and acute
coronary syndromes. At 30-day follow-up, bivalirudin with
provisional GPI not only met the non-inferiority primarycomposite endpoint but was also associated with significantly
lower rate of bleeding.18 The ACUITY trial evaluated bivalir-
udin in 13,819 patients with NSTEMIeACS. It enrolled patients
into three arms: unfractionated or low molecular weight
heparin þ GPI (UFH/LMWH þ GPI), bivalirudin þ GPI and
bivalirudin alone. The composite ischemic endpoint was not
different among the three arms. However, the bivalirudin
alone arm was associated lower rate of bleeding and signifi-
cantly better net clinical outcome compared to UFH/
LMWH þ GPI arm.19 The ISAR-REACT 4 trial, compared biva-
lirudin alone with UFH þ GPI in 1721 NSTEMI patients in the
background of optimal dual antiplatelet loading. The
UFH þ abciximab arm failed to reduce the primary endpoint
and in addition, was associated with increased bleeding.20
The 3602 patient HORIZONS-AMI trial evaluated bivalirudin
with provisional GPI against UFH and planned GPI in the
setting of primary PCI.21 The bivalirudin arm was associated
with reduced rate of primary endpoint of net clinical outcome,
primarily linked to lower incidence of bleeding. In addition
bivalirudin arm was associated with lower mortality that
remained significant at 3-year follow-up. Bivalirudin arm was
associated with increased incidence of acute stent throm-
bosis, especially in patients who did not receive clopidogrel
loading.22 However, at the end of three years, the incidence
was similar between both the arms.With this superior clinical
outcomes, bivalirudin has been given Class I (Level of evidence
e B) recommendation during PCI.7,13,16,175. GPI and newer antiplatelets
Clopidogrel is limited by its slow onset and less potent platelet
inhibition. Even with 600mg of loading dose, it takes at least a
few hours to achieve adequate platelet inhibition which is
associated with increased periprocedural ischemic complica-
tions. This led to the introduction of three newer P2Y12
inhibitors: prasugrel, ticagrelor and cangrelor.23 Prasugrel and
ticagrelor are thienopyridines and administered orally. The
additional benefit of GPI in the background of these drugs is
largely unknown. In TRITONeTIMI 38 trial, a 55% of patients
received GPI. GPI usage over all increased the rates of TIMI
major andminor non-CABG bleeding and however this did not
influence both clinical benefit and the risk of bleeding with
prasugrel comparedwith clopidogrel.24 In the PLATO trial, 27%
of patients received GPI. Similar to prasugrel, ticagrelor also
reduced rates of death, MI, or stroke independent of GPI use.25
Cangrelor is a non-thienopyridine reversible P2Y12 inhibitor,
administered intravenously and provides instant protection
against ischemic events. It also has the advantage of disap-
pearance of antiplatelet activity at cessation of infusion. This
is advantageous in case of major bleeding or emergency sur-
gery. This might further reduce the need for adjunctive GPI
use. However, in the major CHAMPION e PHOENIX trial, none
of the patients received GPI.26 It remains to be seen whether it
gives the same level of protection against ischemic events in
the acute setting. As there have been no randomized studies
specifically evaluating the role of GPI in the background of
newer drugs, current guidelines do not give any definite
recommendations.
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6.1. Bolus only and abbreviated infusion
The recommendation of long duration infusion of GPI
(12e24 h) was based on trial data predating the era of stents
and dual antiplatelets. As thienopyridine loading is expected
to achieve adequate antiplatelet activity within 30 min to few
hours particularly with the newer and potent antiplatelets, it
may be reasonable to limit the use GP IIb-IIIa inhibitor in the
bolus only or bolus and short duration infusion. Two studies
have evaluated bolus only treatment and another study
infusion for less than 2 h27e29 However, the studies included
fewer patients with ACS. Though this approach appears to be
reasonable, currently there are no recommendations on these
protocols.
6.2. Intracoronary infusion
Intracoronary infusion (IC) of GPI resulted in higher receptor
occupancy rates and better thrombus resolution in experi-
mental models.30 Smaller studies have shown improved
epicardial and myocardial perfusion and were also associated
with less adverse events. In the major AIDA-STEMI trial, 2065
STEMI patents undergoing PCI were randomly assigned to
receive abciximab by an IV infusion or directly into the infarct
related coronary artery through guiding catheter. The primary
composite outcome of death, new MI, new heart failure at 90
days, was not different between two groups. However, the IC
administration was associated with reduced incidence of
heart failure.31 In the MRI sub study, there was no significant
difference in the infarct size between the groups.32 In the
INFUSE AMI study, the selective infusion of IC abciximab
through a specialized perfusion catheter was associated with
statistically significant 2% reduction in the infarct size by
MRI.33 Further, in a registry of 104 patients evaluated by IC
administration of GPI was associated with reduction
thrombus burden and improved flow following PCI.34 The
current study by Sengottuvelu and Ravi Sekar also has shown
similar outcomes in STEMI patients undergoing primary PCI.35
The current guidelines have given a Class II b recommenda-
tion for IC - GPI in the setting of PCI during STEMI.7. Do we need them anymore?
From the negative outcomes from multiple trials, it appears
that GPI have little role to play as an adjunct in the current era
of optimal oral antiplatelet loading, newer P2Y12 receptor an-
tagonists and direct thrombin inhibitors. However, it is
important to remember that significant number of patients in
the test arm of most of the trials have received GPI. This
indirectly means that a subgroup of patients still needed GPI
for their periprocedural ischemic events. How many of us
would be comfortable in leaving a residual thrombus without
GPI? Is there any catheterization laboratory that does not have
GPI in house? However, they have to be used judiciously with
specific attention to their bleeding risk. In the current era, GPI
still has a role particularly in patients with high thromboticburden in the setting of ACS, elective PCI complicated by
thrombotic events and in patients who are not adequately
preloaded with dual antiplatelets. Though evidence is not
strong enough, strategies like bolus only, bolus þ abbreviated
infusion or IC infusion might be equally effective with less
bleeding. Thus these drugs though two decades older, are here
to stay till some more effective and safer alternative is
available.r e f e r e n c e s
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